A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France

Adé, Apolline; Bourdon, Olivier; Bussières, J.-F.

doi:10.1016/j.pharma.2017.01.003

Cited by 14 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twenty surveys met the inclusion criteria and were included in this systematic review ( Figure 1). The included studies originated from the United States of America [15][16][17] , Belgium 18,19 , France [20][21][22] , Germany 23,24 , Italy 25 , Ireland 26 , Malta 27 , Hungary 28 , and the United Kingdom (UK) 29 (Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…While this review also included pharmacists, only 4 studies evaluated pharmacists perspectives. 18,20,26,29 Overall, biosimilar prescribing rates varied between country and amongst practitioner type. In a 2015 French survey, for example, 7% of rheumatologists prescribed biosimilars.…”

Section: Discussionmentioning

confidence: 99%

“…17,[23][24][25][26]28,29 Underlying safety (particularly, immunogenicity) and efficacy concerns deterred most physicians from switching patients already tolerating sustained bio-originator therapy to the biosimilar agent. 14,15,16,20,[24][25][26][27][28][29]30 Furthermore, the lack of long-term tolerability data and lack of biosimilar data altogether in extrapolated indications evoked considerable concern, curtailing biosimilar prescribing and uptake. [19][20][21]28,31 Means of health care provider biosimilar education were vaguely described.…”

Section: Discussionmentioning

confidence: 99%

“…Indication extrapolation refers to the approval of a biosimilar for indications held by the bio-originator, but were not directly evaluated during the biosimilar's clinical trials. Approximately 39% of rheumatologists in van Overbeeke et al 19 (Belgium, 2017) and 64% of pharmacists in Adé et al 20 (France, 2017) opposed indication extrapolation. In Danese et al 31 (EU, 2016), 32.2% of gastroenterologists opposed extrapolation across other specialty (e.g., rheumatic) indications and 25% opposed extrapolation across IBD.…”

Section: Biosimilar Prescribing Behaviorsmentioning

confidence: 99%

“…In O'Callaghan et al 26 , 61% of physicians and 58% of pharmacists believed switching should solely be the prescriber's decision. In Adé et al 20 (France, 2017), 95% of pharmacists believed interchanging biosimilars for bio-originators was a joint physician-pharmacist responsibility.…”

Section: Biosimilar Prescribing Behaviorsmentioning

confidence: 99%

See 4 more Smart Citations

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

Leonard

Wascovich

Oskouei³

et al. 2019

JMCP

105

133

View full text Add to dashboard Cite

Background: Newly developed biosimilar agents confer significant cost saving advantages, yielding the potential to mitigate rising drug costs and expand patient access to care for important biologic therapies. Biosimilar market uptake greatly depends upon healthcare provider willingness to promote, prescribe, and use biosimilars in clinical practice. Objective: To perform a systematic review evaluating current United States (U.S.) and European (EU) health care provider knowledge, perceptions, and prescribing behaviors of biosimilar medicines to assess the need for clinician-directed, biosimilar education. Methods: An electronic literature search was conducted using journal databases, including PubMed, Embase, and Cochrane Library. Terms related to biosimilar agents, survey questionnaires, and education were used. Two independent reviewers evaluated 158 citations published from January 1, 2014 to March 5, 2018, that were the result of this search. Studies in English were included if they surveyed U.S. or EU physician and/or pharmacist knowledge, attitudes, and/or prescribing preferences of biosimilar drugs. Overall trends in prescribing behavior and perceptions were abstracted. Results: A total of 20 studies met inclusion criteria. Three studies originated from the U.S. and 17 from Europe. Hospital specialists, gastroenterologists, and rheumatologists were the most frequently surveyed practitioners. Percent of biosimilar prescribing varied widely between countries and within similar practice fields. If used, biosimilars were predominantly prescribed in biologic-treatment naïve patients. An overall lack of biosimilar familiarity in both U.S. and EU health care settings accompanied concerns about biosimilar safety, efficacy, extrapolation, and interchangeability. Detailed descriptions of biosimilar education programs were lacking from the literature. Conclusions: Findings from this review indicate that U.S. and EU healthcare providers still approach biosimilar medicines with caution, citing limited biosimilar knowledge, low prescribing comfort, and safety and efficacy concerns as main deterrents for biosimilar use. To realize the full cost-saving potential of biosimilar medicines, clinician-directed, biosimilar education will be imperative to address gaps in biosimilar knowledge, facilitate prescribing changes, and ultimately increase biosimilar use.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Biosimilar Prescribing Behaviorsmentioning

confidence: 99%

Section: Biosimilar Prescribing Behaviorsmentioning

confidence: 99%

See 3 more Smart Citations

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

Leonard

Wascovich

Oskouei³

et al. 2019

JMCP

105

133

View full text Add to dashboard Cite

show abstract

Knowledge Areas and Competency Standards on Biologic Medicines for Pharmacists and Pharmacy Students

Ramzan

Kahlaee

2020

Biologics, Biosimilars, and Biobetters

View full text Add to dashboard Cite

Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Background Biosimilars are expected to decrease growing health care expenditures. Given that uptake of biosimilars has been modest, automatic substitution has been suggested to increase their use, but the practice is not yet allowed or implemented in many jurisdictions. Methods A systematic review was performed by searching databases Scopus, Medline (Ovid), CINAHL, and Web of Science. Peer-reviewed, original studies written in English and published during the period January 1, 2006 to April 24, 2021 reporting any interventions, pilots or any other studies including experiences or perceptions of any relevant stakeholders on automatic substitution of biologics were included without limitation by setting or geography. The quality of the included studies were evaluated by pre-determined criteria. Results Altogether, 27 studies fulfilled the inclusion criteria, of which 23 were surveys, and four semi-structured interviews reporting mainly stakeholders' perceptions on automatic substitution. Most of the studies (56%, 15/27) were from Europe. Studies were conducted among prescribers (n = 12), pharmacists (n = 5), patients (n = 4), payers (n = 1), and mixed stakeholders (n = 5). The primary objective of the majority (81%, 22/27) of the studies was to investigate some other biosimilar topic than automatic substitution. The reported perceptions of substitution were mainly negative. Studies evaluating risks, safety or effectiveness, or reporting real-life experiences of biologic substitution were lacking except one intervention and two prospective risk management studies. The overall quality of the studies was low to moderate, and the results were not generalizable due to convenience sampling not representing the populations of interest, and low response rates. Conclusions The current research evidence on the automatic substitution of biologics is scarce and of low to moderate quality, reflecting low stakeholder knowledge and their cautious attitude towards biosimilars. The safe and efficient implementation of automatic substitution requires well-designed practices, pilot studies, and evolving legislation.

show abstract

A survey of pharmacists’ knowledge and views of biosimilars in Quebec and France

Cited by 14 publications

References 9 publications

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review

Knowledge Areas and Competency Standards on Biologic Medicines for Pharmacists and Pharmacy Students

Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review

Contact Info

Product

Resources

About